NCT01496976 2025-12-19
Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
Clinical Trials
3 trialsNCT01258933 2025-10-01
Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01352312 2025-04-29
Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma
Thomas Jefferson University
Phase 1 Terminated